Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Payables (2016 - 2025)

Tandem Diabetes Care's Payables history spans 13 years, with the latest figure at $47.1 million for Q4 2025.

  • For Q4 2025, Payables rose 5.22% year-over-year to $47.1 million; the TTM value through Dec 2025 reached $47.1 million, up 5.22%, while the annual FY2025 figure was $47.1 million, 5.22% up from the prior year.
  • Payables reached $47.1 million in Q4 2025 per TNDM's latest filing, down from $47.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $61.5 million in Q3 2022 to a low of $27.0 million in Q3 2021.
  • Average Payables over 5 years is $46.6 million, with a median of $48.0 million recorded in 2024.
  • Peak YoY movement for Payables: surged 128.12% in 2022, then fell 25.01% in 2023.
  • A 5-year view of Payables shows it stood at $28.0 million in 2021, then soared by 98.81% to $55.7 million in 2022, then dropped by 11.02% to $49.6 million in 2023, then dropped by 9.79% to $44.7 million in 2024, then rose by 5.22% to $47.1 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Payables are $47.1 million (Q4 2025), $47.5 million (Q3 2025), and $55.8 million (Q2 2025).